SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
Related Posts
Tags: ability, announce, clinical, efficacy, enhance, examining, h1n1, positive, preliminary, response, results, sciclone, sigma, study, vaccine, zadaxins
This entry was posted on Saturday, January 16th, 2010 at 7:01 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



